Special Issue

Topic: Resistance to Cancer Immunotherapy

A Special Issue of Cancer Drug Resistance

ISSN 2578-532X (Online)

Submission deadline: 31 Jan 2020

Guest Editor(s)

Prof. Gerhard Hamilton
Department of Surgery, Medical University of Vienna, Vienna, Austria.

Special Issue Introduction

Cancer immunotherapy, especially in the form of the inhibition of checkpoint molecules, has significantly improved the outlook of melanoma, lung cancer and other patients. However, of the approximately 45% of cancer patients eligible for immunotherapy, only about 13% of cases are responders leaving the remaining population exposed to a therapy which has fewer side effects than chemotherapy but is not free of a range of adverse events. Assessment of PD-L1 expression and tumor mutational burden (TMB) enriches suitable patients but cannot actually predict responses. Furthermore, tumors may become resistant to immunotherapy either by changing their own characteristics or by generating an immunosuppressive microenvironment. For this issue, work on all aspects of mechanisms that renders immunotherapy ineffective is invited. This comprises the range of different immune checkpoint molecules and the modulation of their expression, tumor infiltration, immunosuppressive leukocyte populations as well as the effects of chemotherapy in combination trials and more. In particular, the ongoing study of drugs that can convert a cold tumor to a hot one or provide accessory stimulation of the immune system is of special interest to overcome resistance. Another current focus is the selection of markers to rapidly evaluate the success of an ongoing immunotherapy, including the detection of resistance. Future directions for the improvement of immunotherapy may involve combination therapy with other immune modulators, oncolytic viruses, vaccines, radiation treatment, chemotherapy, targeted therapy, or antiangiogenic therapy to achieve its full potential and to overcome resistance. In summary, the objective of this series is to explore the current successes and failures, and discuss the future directions of immunotherapy as a means of treating cancer.

Keywords

Cancer immunotherapy, checkpoint inhibition, resistance, CTLA-4, PD-L1, tumor mutational burden

Submission Deadline

31 Jan 2020

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=333
Submission Deadline: 31 Jan 2020
Contacts: Susan Song, Assistant Editor, susan@cdrjournal.com
Bill Li, Managing Editor, bill@cdrjournal.com or editorial@cdrjournal.com

Published Articles

Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade

Open Access Review DOI: 10.20517/cdr.2020.41 11 Oct 2020
Views: Downloads:
Download PDF

Manipulation of the immune system by non-small cell lung cancer and possible therapeutic interference

Open Access Review DOI: 10.20517/cdr.2020.40 11 Sep 2020
Views: Downloads:
Download PDF

The tumor microenvironment of pancreatic adenocarcinoma and immune checkpoint inhibitor resistance: a perplex relationship

Open Access Review DOI: 10.20517/cdr.2020.48 3 Sep 2020
Views: Downloads:
Download PDF

Resistance to cancer immunotherapy in metastatic renal cell carcinoma

Open Access Review DOI: 10.20517/cdr.2020.16 1 Jul 2020
Views: Downloads:
Download PDF

A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy

Open Access Review DOI: 10.20517/cdr.2020.11 17 Jun 2020
Views: Downloads:
Download PDF

Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors

Open Access Original Article DOI: 10.20517/cdr.2020.07 17 Jun 2020
Views: Downloads:
Download PDF

Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?

Open Access Review DOI: 10.20517/cdr.2020.14 10 May 2020
Views: Downloads:
Download PDF

The dark side of immunotherapy: pancreatic cancer

Open Access Review DOI: 10.20517/cdr.2020.13 10 May 2020
Views: Downloads:
Download PDF

Therapeutic modulation of the CD47-SIRPα axis in the pediatric tumor microenvironment: working up an appetite

Open Access Review DOI: 10.20517/cdr.2020.12 10 May 2020
Views: Downloads:
Download PDF

Cell-mediated immune resistance in cancer

Open Access Perspective DOI: 10.20517/cdr.2019.98 1 Jan 2020
Views: Downloads:
Download PDF
Cancer Drug Resistance
ISSN 2578-532X (Online)
Follow Us

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/